Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Keyphrases

• Multiple Sclerosis 100%
• International Registry 100%
• Disease-modifying Therapy 100%
• National Registry 100%
• Longitudinal Analysis 100%
• Pediatric multiple Sclerosis 100%
• Disability Worsening 100%
• Disability 58%
• High-efficacy Therapy 50%
• Expanded Disability Status Scale 41%
• Minimal Disability 41%
• Mild Disability 25%
• Hazard Ratio 16%
• Australia 16%
• Young People 16%
• Progressive multiple Sclerosis 16%
• Gait Impairment 16%
• MSBase 16%
• High Efficacy Disease-modifying Therapies 16%
• Age of Onset 8%
• National Health 8%
• Neurological Impairment 8%
• Interferon-β (IFN-β) 8%
• 18 Years Old 8%
• Natural Course 8%
• Health Research 8%
• Natalizumab 8%
• Confirmed Diagnosis 8%
• Longitudinal Data 8%
• Related Disorders 8%
• Accruals 8%
• Rituximab 8%
• Mitoxantrone 8%
• Glatiramer Acetate 8%
• Medical Research Council 8%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 8%
• Pediatric Onset 8%
• Large Reduction 8%
• Ocrelizumab 8%
• Time Change 8%
• Teriflunomide 8%
• Alemtuzumab 8%
• Fingolimod 8%
• Dimethyl Fumarate 8%
• Disability Improvement 8%
• Lived Experience 8%
• Cladribine 8%
• Multistate Model 8%
• Moderate Disability 8%
• Daclizumab 8%
• 41 Countries 8%
• Postdoctoral Fellowship 8%

Medicine and Dentistry

• Pediatrics 100%
• Multiple Sclerosis 100%
• Disease Modifying Therapy 100%
• Expanded Disability Status Scale 29%
• Hazard Ratio 11%
• Clinician 5%
• Onset Age 5%
• Beta Interferon 5%
• Medical Research 5%
• Personal Experience 5%
• Rituximab 5%
• Autologous Hematopoietic Stem Cell Transplantation 5%
• Disease 5%
• Natalizumab 5%
• Ocrelizumab 5%
• Mitoxantrone 5%
• Alemtuzumab 5%
• Fingolimod 5%
• Cladribine 5%
• Teriflunomide 5%
• Glatiramer 5%
• Fumaric Acid Dimethyl Ester 5%
• Daclizumab 5%
• Primary Outcome 5%

Neuroscience

• Multiple Sclerosis 100%
• Expanded Disability Status Scale 33%
• Secondary Progressive Multiple Sclerosis 13%
• Natalizumab 6%
• Glatiramer Acetate 6%
• Rituximab 6%
• Beta Interferon 6%
• Ocrelizumab 6%
• Mitoxantrone 6%
• Teriflunomide 6%
• Alemtuzumab 6%
• Daclizumab 6%
• Cladribine 6%
• Hematopoietic Cell 6%
• Fingolimod 6%